RVNC - Revance Therapeutics EPS misses by $0.05 misses on revenue February, 24 2020 04:15 PM Revance Therapeutics Inc. Revance Therapeutics (NASDAQ:RVNC): Q4 GAAP EPS of -$0.99 misses by $0.05.More news on: Revance Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...